Ascendis Pharma A/S (ASND) Rating Increased to Strong-Buy at ValuEngine

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report released on Wednesday.

Other analysts have also recently issued reports about the company. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, August 25th. Canaccord Genuity assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, August 7th. They set a “buy” rating and a $81.00 price target on the stock. Wells Fargo & Co increased their price target on Ascendis Pharma A/S from $83.00 to $88.00 and gave the stock an “outperform” rating in a research report on Thursday, August 30th. Wedbush set a $79.00 price target on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Thursday, August 30th. Finally, Zacks Investment Research upgraded Ascendis Pharma A/S from a “hold” rating to a “strong-buy” rating and set a $72.00 price target on the stock in a research report on Tuesday, October 30th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $77.56.

Shares of Ascendis Pharma A/S stock opened at $64.99 on Wednesday. Ascendis Pharma A/S has a twelve month low of $36.07 and a twelve month high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.29. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.01 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth $350,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth $361,000. Meadow Creek Investment Management LLC boosted its stake in shares of Ascendis Pharma A/S by 12.1% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 6,952 shares of the biotechnology company’s stock worth $462,000 after acquiring an additional 748 shares in the last quarter. Glen Harbor Capital Management LLC boosted its stake in shares of Ascendis Pharma A/S by 12.1% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 952 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 153.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 5,107 shares in the last quarter. 95.60% of the stock is owned by hedge funds and other institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Cost of equity and a company’s balance sheet

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply